
Cardiovascular diseases remain a leading cause of global mortality. Potassium channel openers (PCOs) offer cardioprotective effects through modulation of cellular excitability and mitochondrial function. This narrative review critically evaluates mechanistic and clinical evidence published between 2000 and 2024, focusing on nicorandil and diazoxide in ischemia-reperfusion injury and cardiotoxicity. We examine mitochondrial ATP-sensitive potassium (mitoKATP) and large-conductance calcium-activated potassium (BKCa) channels, their roles in mitochondrial energetics and redox homeostasis, and their interplay with inhibition of mitochondrial permeability transition pore opening. Clinical contexts include cardioplegic arrest, myocardial infarction, and chemotherapy-induced cardiotoxicity. PCOs, particularly nicorandil, combine mitochondrial protection with hemodynamic benefits, with evidence supporting reductions in major adverse cardiovascular events and preservation of mitochondrial integrity. However, routine clinical integration remains constrained by translational gaps, inconsistent electrophysiological effects, and dose-limiting adverse events, including hypotension. Future development should prioritize mitochondrial channel subtype selectivity, particularly targeted mitoKATP and BKCa modulation, alongside well-designed randomized controlled trials to establish clinical efficacy and safety. These advances may strengthen the role of PCOs in cardiovascular medicine while minimizing systemic vascular adverse effects.
Hypertension frequently coexists with metabolic abnormalities that contribute to cardiovascular risk. The triglyceride-glucose (TyG) index is a simple surrogate marker of insulin resistance that may also reflect early cardiometabolic and cardiovascular vulnerability. This narrative review examines the prognostic relevance of TyG for all-cause mortality, cardiovascular mortality, and fatal or non-fatal cardiovascular events in hypertension. PubMed, Embase, and the Cochrane Library were searched through 5 October 2026, without date or language restrictions. Evidence from primary hypertensive cohorts generally supports associations between higher TyG and adverse outcomes, although their magnitude and shape vary, with both linear and nonlinear patterns reported. Findings are most consistent among hypertensive patients with diabetes, whereas results from other high-risk settings and hypertension-specific subgroup analyses are more heterogeneous. Differences in TyG calculation, modeling, glycemic status, clinical settings, and overlapping cohorts complicate comparisons across studies. Overall, TyG may represent a readily available, low-cost marker of early cardiometabolic and cardiovascular vulnerability, beyond its role as a surrogate of insulin resistance, with potential to refine cardiovascular risk stratification in hypertension. Further prospective validation should establish its incremental predictive value beyond conventional cardiovascular risk factors and established risk scores.
Transseptal puncture (TSP) is the first step in percutaneous left-heart interventions including atrial fibrillation ablation, left atrial appendage occlusion, and percutaneous mitral valve repair/replacement. Current TSP techniques remain limited by suboptimal imaging visualization, lack of precise control over puncture sites, and a steep learning curve. The Protaryx transseptal puncture device was designed to address these limitations by incorporating a novel atraumatic highly echogenic deployable and retractable nitinol mesh end effector mounted on an extendable catheter. The key advantages of the Protaryx TSP device are the maneuverability of the extendable catheter and the visibility of the end effector that combine to enable precise targeting of the fossa ovalis during TSP. Here, we provide an overview of challenges with transseptal puncture, an overview of the Protaryx device, and early clinical evidence. This includes results of the 5-patient prospective non-randomized observational first-in-human experience with the Protaryx TSP catheter. This study demonstrated early feasibility and safety, with rapid on-target puncture of the fossa ovalis, zero adverse events, and 100% success of structural heart interventions following TSP. The United States Food and Drug Administration (FDA) approval of the Protaryx device has increased options for interventional cardiologists and electrophysiologists seeking to streamline left-sided structural heart intervention.